Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | PAICS | P22234 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028275 | 0.88 | POLB (0.40) | STK17BGAKALOX15CHEK1PAICS | |
| SCHEMBL6029616 | 0.87 | CDK2 (0.37) | HPGDSTK17BALOX15ROCK2CCNT1 | |
| SCHEMBL6030139 | 0.85 | ALOX15 (0.37) | HPGDSTK17BALOX15ROCK2CCNT1 | |
| SCHEMBL6028800 | 0.83 | LMNA (0.38) | HPGDALOX15ROCK2CHEK1CCNT1 | |
| SCHEMBL6029737 | 0.82 | CDK9 (0.37) | HPGDSTK17BALOX15ROCK2CHEK1 | |
| SCHEMBL6028781 | 0.82 | ALOX15 (0.36) | HPGDSTK17BGAKALOX15ROCK2 | |
| SCHEMBL7833614 | 0.82 | AKT1 (0.38) | STK17BGAKROCK2 | |
| SCHEMBL6029139 | 0.82 | KDM4E (0.41) | HPGD | |
| SCHEMBL6028621 | 0.82 | LMNA (0.38) | HPGDSTK17BGAKALOX15ROCK2 | |
| SCHEMBL6029125 | 0.79 | MAPK1 (0.38) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984643-B2 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1521582-A1 | 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-13 | — | — | EP | disclosed |
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2004004731-A1 | 2, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS IX | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | HPGD 2040/4885STK17B 3891/4885GAK 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.